Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. 

CEO
Belén Garijo López
CEOBelén Garijo López
Employees
76,493
Employees76,493
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1994
Founded1994
Employees
76,493
Employees76,493

SNY Key Statistics

Market cap
107.17B
Market cap107.17B
Price-Earnings ratio
22.42
Price-Earnings ratio22.42
Dividend yield
4.04%
Dividend yield4.04%
Average volume
2.85M
Average volume2.85M
High today
$44.10
High today$44.10
Low today
$43.52
Low today$43.52
Open price
$43.93
Open price$43.93
Volume
2.21M
Volume2.21M
52 Week high
$52.68
52 Week high$52.68
52 Week low
$40.89
52 Week low$40.89

SNY News

TipRanks 4h
Sanofi Updates Share Capital and Voting Rights as of July 31, 2026

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Simply Wall St 21h
Nurix Therapeutics Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche

Nurix Therapeutics recently reported earning a US$10 million milestone payment from Sanofi for advancing its oral STAT6 degrader into a Phase 1 trial, while als...

Nurix Therapeutics Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche
The Motley Fool 1d
Kymera Therapeutics Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Founder, President and Chief Executive Officer - Nello Mainolfi Chief...

Kymera Therapeutics Q2 2026 Earnings Call Transcript

Analyst ratings

57%

of 7 ratings
Buy
42.9%
Hold
57.1%
Sell
0%

More SNY News

TipRanks 2d
Sanofi price target lowered to EUR 82 from EUR 86 at Morgan Stanley

Morgan Stanley analyst Sarita Kapila lowered the firm’s price target on Sanofi (SNY) to EUR 82 from EUR 86 and keeps an Equal Weight rating on the shares. Unlo...

TipRanks 3d
Sanofi facing shortages of two drugs for Pompe disease, STAT reports

Sanofi (SNY) is facing shortages of Myozyme and Nexviazyme for Pompe disease after manufacturing and quality-control issues at its Waterford facility, which was...

Simply Wall St 5d
Is Sanofi Cheap Following MenQuadfi Approval For Infants? - simplywall.st

...

Is Sanofi Cheap Following MenQuadfi Approval For Infants? - simplywall.st
TipRanks 6d
Major Pharma Giant Deepens Its Bet on Attovia Therapeutics With a Fresh Multi-Million-Dollar Buy

New insider activity at Attovia Therapeutics, Inc. ( (ATTO) ) has taken place on August 7, 2026. Unlock powerful investing tools with TipRanks Premium to make...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.